Breakout Setups
NANO.PA appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
NANOBIOTIX (NANO.PA) Stock Price & Overview
EPA:NANO • FR0011341205
Current stock price
27.2 EUR
-0.52 (-1.88%)
Last:
The current stock price of NANO.PA is 27.2 EUR. Today NANO.PA is down by -1.88%. In the past month the price increased by 1.17%. In the past year, price increased by 869.23%.
NANO.PA Key Statistics
52-Week Range2.79 - 35.2
Current NANO.PA stock price positioned within its 52-week range.
1-Month Range24.05 - 29.3
Current NANO.PA stock price positioned within its 1-month range.
- Market Cap
- 1.316B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.50
- Dividend Yield
- N/A
NANO.PA Stock Performance
Today
-1.88%
1 Week
+5.16%
1 Month
+1.17%
3 Months
+55.38%
Longer-term
6 Months +71.96%
1 Year +869.23%
2 Years +409.09%
3 Years +1,431.49%
5 Years +111.93%
10 Years +60.88%
NANO.PA Stock Chart
NANO.PA Stock Screens
NANO.PA currently appears in the following ChartMill screener lists.
NANO.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NANO.PA. When comparing the yearly performance of all stocks, NANO.PA is one of the better performing stocks in the market, outperforming 99.7% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NANO.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NANO.PA. NANO.PA may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NANO.PA Earnings
On March 31, 2026 NANO.PA reported an EPS of -0.39 and a revenue of 5.96M. The company missed EPS expectations (-170.16% surprise) and missed revenue expectations (-90.05% surprise).
Next Earnings DateMay 19, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-€0.39
Revenue Reported5.955M
EPS Surprise -170.16%
Revenue Surprise -90.05%
NANO.PA Forecast & Estimates
12 analysts have analysed NANO.PA and the average price target is 29.1 EUR. This implies a price increase of 7% is expected in the next year compared to the current price of 27.2.
For the next year, analysts expect an EPS growth of -24.95% and a revenue growth 9.99% for NANO.PA
Analysts
Analysts85
Price Target29.1 (6.99%)
EPS Next Y-24.95%
Revenue Next Year9.99%
NANO.PA Groups
Sector & Classification
NANO.PA Financial Highlights
Over the last trailing twelve months NANO.PA reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 65.28% compared to the year before.
Income Statements
Revenue(TTM)7.84M
Net Income(TTM)-23.96M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.36% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%60.2%
Sales Q2Q%136.13%
EPS 1Y (TTM)65.28%
Revenue 1Y (TTM)167.56%
NANO.PA Ownership
Ownership
Inst Owners30.68%
Shares48.40M
Float40.51M
Ins Owners0.63%
Short Float %N/A
Short RatioN/A
NANO.PA Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 31.06 | 44.565B | ||
| ARGX | ARGENX SE | 30.48 | 44.006B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.431B | ||
| 2X1 | ABIVAX SA | N/A | 8.246B | ||
| ABVX | ABIVAX SA | N/A | 7.961B | ||
| GLPG | GALAPAGOS NV | N/A | 1.638B | ||
| GXE | GALAPAGOS NV | N/A | 1.612B | ||
| PHGN | PHARMING GROUP NV | 49.55 | 1.054B | ||
| PHARM | PHARMING GROUP NV | 49.55 | 1.05B | ||
| IVA | INVENTIVA SA | N/A | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 996.493M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 991.483M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About NANO.PA
Company Profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Info
IPO: 2012-10-29
NANOBIOTIX
60 rue de Wattignies
Paris ILE-DE-FRANCE FR
Employees: 103
Phone: 33140260470
NANOBIOTIX / NANO.PA FAQ
What does NANO do?
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
What is the current price of NANO stock?
The current stock price of NANO.PA is 27.2 EUR. The price decreased by -1.88% in the last trading session.
Does NANOBIOTIX pay dividends?
NANO.PA does not pay a dividend.
How is the ChartMill rating for NANOBIOTIX?
NANO.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about NANOBIOTIX (NANO.PA) stock?
12 analysts have analysed NANO.PA and the average price target is 29.1 EUR. This implies a price increase of 7% is expected in the next year compared to the current price of 27.2.
Can you provide the PE ratio for NANO stock?
NANOBIOTIX (NANO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
Would investing in NANOBIOTIX be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NANO.PA.